Palisade Bio, Inc. (NASDAQ:PALI) Receives Consensus Rating of “Buy” from Analysts

Shares of Palisade Bio, Inc. (NASDAQ:PALI) have been given a consensus recommendation of “Buy” by the ten research firms that are presently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell rating, seven have assigned a buy rating and two have given a strong buy rating to the company. The average 1 year price target among analysts that have covered the stock in the last year is $9.00.

A number of equities analysts have issued reports on the company. Weiss Ratings downgraded Palisade Bio from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, July 14th. Oppenheimer started coverage on Palisade Bio in a report on Thursday, July 23rd. They issued an “outperform” rating and a $8.00 target price on the stock. Wall Street Zen upgraded Palisade Bio from a “sell” rating to a “hold” rating in a report on Saturday, July 25th. LADENBURG THALM/SH SH raised Palisade Bio to a “strong-buy” rating in a research report on Thursday, June 25th. Finally, HC Wainwright reiterated a “buy” rating and set a $2.00 price target on shares of Palisade Bio in a report on Tuesday, June 30th.

Palisade Bio Trading Up 9.7%

Palisade Bio stock opened at $2.15 on Friday. The firm has a market capitalization of $374.68 million, a price-to-earnings ratio of -2.13 and a beta of 1.52. The firm’s fifty day moving average price is $1.95 and its two-hundred day moving average price is $1.91. Palisade Bio has a 1-year low of $0.53 and a 1-year high of $2.85.

Palisade Bio (NASDAQ:PALI) last posted its earnings results on Monday, August 10th. The company reported ($0.05) EPS for the quarter, hitting the consensus estimate of ($0.05). The business had revenue of $0.50 million for the quarter, compared to the consensus estimate of $0.50 million. On average, research analysts forecast that Palisade Bio will post -0.22 EPS for the current year.

Insiders Place Their Bets

In other news, Director Robert Jr. Baltera bought 30,000 shares of the stock in a transaction dated Tuesday, July 7th. The stock was bought at an average price of $2.03 per share, for a total transaction of $60,900.00. Following the completion of the acquisition, the director directly owned 416,904 shares in the company, valued at approximately $846,315.12. This trade represents a 7.75% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Mitchell Lawrence Jones sold 51,880 shares of the firm’s stock in a transaction dated Tuesday, July 7th. The shares were sold at an average price of $2.05, for a total transaction of $106,354.00. Following the transaction, the insider directly owned 94,009 shares in the company, valued at $192,718.45. The trade was a 35.56% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have bought 125,000 shares of company stock valued at $250,100 in the last three months. 0.07% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Palisade Bio

Institutional investors have recently added to or reduced their stakes in the company. XTX Topco Ltd lifted its position in shares of Palisade Bio by 53.8% during the 4th quarter. XTX Topco Ltd now owns 21,669 shares of the company’s stock worth $51,000 after buying an additional 7,584 shares in the last quarter. Cetera Investment Advisers purchased a new position in shares of Palisade Bio in the 4th quarter worth approximately $25,000. Schonfeld Strategic Advisors LLC bought a new position in shares of Palisade Bio in the fourth quarter valued at approximately $26,000. Virtu Financial LLC bought a new position in shares of Palisade Bio in the fourth quarter valued at approximately $28,000. Finally, Atom Investors LP purchased a new stake in shares of Palisade Bio during the fourth quarter valued at approximately $33,000. 11.79% of the stock is owned by institutional investors.

About Palisade Bio

Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.